Amit Singal, MD, MS

Articles

Future Directions in the Management of Hepatocellular Carcinoma

January 2nd 2024

To close, Dr. Saeed and Dr. Singal share their excitement for the future landscape, emerging agents and treatment strategies for patients with HCC.

Additional Data Updates from AASLD 2023

December 26th 2023

Drs Saeed and Singal discuss additional data presented at AASLD 2023 related to frontline systemic therapies and emerging combinations in unresectable HCC.

Real-World Data and Impact on Treatment Selection in uHCC

December 26th 2023

Expert oncologists review real-world data and discuss the impact on treatment selection in uHCC.

Efficacy and Safety Outcomes in Combination Immunotherapy for uHCC

December 19th 2023

An expert analysis in data surrounding treatment outcomes in combination regimens, noting immune-mediate adverse events and overall impact on treatment response.

AASLD 2023 Updates: HIMALAYA Trial for uHCC

December 19th 2023

Dr. Saeed outlines the use of combination tremelimumab plus durvalumab in uHCC, discussing updates from the HIMALAYA trial presented at AASLD 2023.

Atezolizumab plus Bevacizumab in the Treatment of Unresectable HCC

December 12th 2023

A comprehensive review of clinical data of atezolizumab plus bevacizumab for the treatment of unresectable HCC.

The Evolving Landscape of Hepatocellular Carcinoma

December 12th 2023

Anwaar Saeed, MD, and Amit Singal, MD, discuss the evolving treatment landscape for hepatocellular carcinoma, highlighting FDA approvals and the utility of clinical biomarkers.

The Future of Liver Function Assessments in HCC

October 31st 2023

Experts emphasize the importance of using multiple liver function assessments for more comprehensive patient evaluation in hepatocellular carcinoma treatment.

Rivoceranib plus Camrelizumab for First-Line Treatment of HCC: Data from CARES-310

October 25th 2023

Rachna Shroff, MD, MS, FASCO, shares data from the CARES-310 study showing improved progression-free and overall survival in patients with hepatocellular carcinoma treated with camrelizumab and rivoceranib compared to sorafenib, regardless of liver function.

Key Outcomes Data in Patients With HCC Based on Liver Function

October 25th 2023

Amit Singal, MD, reviews analyses of the HIMALAYA and KEYNOTE-240 trials, focusing on the impact of liver function via ALBI grades on treatment outcomes and safety in patients with hepatocellular carcinoma.

Updates in First-Line Systemic Therapy for Patients With HCC

October 17th 2023

Arndt Vogel, MD, discusses the post-hoc analyses of two key clinical trials focusing on the impact of liver function, measured by ALBI and Child-Pugh scores, on outcomes in hepatocellular carcinoma treatments.

Assessing Liver Function in Patients With HCC: The MELD Score

October 17th 2023

Rachna Shroff, MD, MS, FASCO, and Amit Singal, MD, discuss the use of various liver function assessment scores—Child-Pugh, ALBI, and MELD—in the care of patients with hepatocellular carcinoma, emphasizing their pros, cons, and roles in treatment decision-making.

Assessing Liver Function in Patients With HCC: The Child-Pugh Score

October 10th 2023

Arndt Vogel, MD, explains that the Child-Pugh score, although simpler to calculate than the ALBI score, sometimes lacks granularity in assessing liver function in hepatocellular carcinoma patients; however, both scoring systems are considered valuable tools in clinical settings and trials for evaluating liver function's prognostic impact on treatment outcomes.

Assessing Liver Function in Patients With HCC: The ALBI Score

October 10th 2023

The ALBI score, originally developed to stratify cirrhotic patients undergoing resection, has evolved into a vital tool for assessing prognosis and treatment efficacy in various stages of hepatocellular carcinoma and is now being explored for its utility in other liver-related diseases.

Importance of Assessing Liver Function in HCC

October 3rd 2023

Drs Vogel and Singal discuss the critical importance of assessing liver function in hepatocellular carcinoma patients, as it impacts prognosis and treatment strategies; they mention the evolution from Child-Pugh scoring to the ALBI score, which uses albumin and bilirubin levels, for a more objective evaluation of liver health.

Risk Factors of Hepatocellular Carcinoma (HCC)

October 3rd 2023

Rachna Shroff, MD, MS, FASCO, discusses hepatocellular carcinoma, noting its rising global incidence and identifying underlying liver cirrhosis as a key risk factor influenced by conditions like viral hepatitis and fatty liver disease; diagnosis often involves radiographic imaging and triple-phase CT and MRI scans, while treatment necessitates a multidisciplinary approach involving hepatologists, surgeons, and other specialists.

HCC International Clinical Trials

February 2nd 2023

Closing the discussion on HCC systemic therapies, Drs Abou-Alfa, Lewandowski and Singal review international clinical trials and access to treatments.

Novel Strategies: Combining Systemic and Local Therapies

February 2nd 2023

Ghassan Abou-Alfa, MD, Robert Lewandowski, MD, FSIR, and Amit Singal, MD discuss potential novel combination therapies including immune checkpoint inhibitors plus tyrosine kinase inhibitors plus local-regional therapeutic strategies.

Real-World Evidence on Use of Immune Checkpoint Inhibitor Combinations and Clinical Trial Endpoints

January 26th 2023

Experts in liver cancer treatment provide insight on real-world trials of immune checkpoint inhibitor combinations in HCC and opine on trial endpoints when immune therapy is utilized.

Immune Checkpoint Inhibitors and Their Effects on Liver Function

January 26th 2023

Drs Abou-Alfa, Singal, and Lewandowski discuss use of immune checkpoint inhibitors and liver function.